MorphoSys AG reported a loss for the second quarter due largely to an unfavourable comparison with the previous period when earnings were inflated by a licensing deal with GlaxoSmithKline Plc. However, the company expects its loss for the year as a whole to be at the lowest end of previous guidance.
